Compare VENUS REMEDIES with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES TORRENT PHARMA VENUS REMEDIES/
TORRENT PHARMA
 
P/E (TTM) x -1.0 56.9 - View Chart
P/BV x 0.1 6.0 1.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 VENUS REMEDIES   TORRENT PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
TORRENT PHARMA
Mar-18
VENUS REMEDIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,550 8.1%   
Low Rs611,144 5.3%   
Sales per share (Unadj.) Rs301.8354.7 85.1%  
Earnings per share (Unadj.) Rs-24.940.1 -62.1%  
Cash flow per share (Unadj.) Rs2.564.2 4.0%  
Dividends per share (Unadj.) Rs014.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs293.3273.1 107.4%  
Shares outstanding (eoy) m12.34169.22 7.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.8 8.2%   
Avg P/E ratio x-3.833.6 -11.2%  
P/CF ratio (eoy) x36.721.0 175.2%  
Price / Book Value ratio x0.34.9 6.5%  
Dividend payout %034.9 0.0%   
Avg Mkt Cap Rs m1,154227,897 0.5%   
No. of employees `0000.914.7 6.3%   
Total wages/salary Rs m39311,353 3.5%   
Avg. sales/employee Rs Th4,026.14,083.0 98.6%   
Avg. wages/employee Rs Th425.0772.3 55.0%   
Avg. net profit/employee Rs Th-331.8461.3 -71.9%   
INCOME DATA
Net Sales Rs m3,72460,021 6.2%  
Other income Rs m232,988 0.8%   
Total revenues Rs m3,74763,009 5.9%   
Gross profit Rs m39513,493 2.9%  
Depreciation Rs m3384,086 8.3%   
Interest Rs m3543,085 11.5%   
Profit before tax Rs m-2759,310 -3.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m322,529 1.2%   
Profit after tax Rs m-3076,781 -4.5%  
Gross profit margin %10.622.5 47.2%  
Effective tax rate %-11.527.2 -42.3%   
Net profit margin %-8.211.3 -72.9%  
BALANCE SHEET DATA
Current assets Rs m2,63852,623 5.0%   
Current liabilities Rs m2,30552,022 4.4%   
Net working cap to sales %8.91.0 892.3%  
Current ratio x1.11.0 113.1%  
Inventory Days Days135120 113.3%  
Debtors Days Days4676 60.8%  
Net fixed assets Rs m4,87185,016 5.7%   
Share capital Rs m123846 14.6%   
"Free" reserves Rs m3,49645,376 7.7%   
Net worth Rs m3,61946,222 7.8%   
Long term debt Rs m1,37441,115 3.3%   
Total assets Rs m7,509142,432 5.3%  
Interest coverage x0.24.0 5.5%   
Debt to equity ratio x0.40.9 42.7%  
Sales to assets ratio x0.50.4 117.7%   
Return on assets %0.66.9 9.1%  
Return on equity %-8.514.7 -57.8%  
Return on capital %1.614.2 11.1%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m014,580 0.0%   
Fx outflow Rs m5173,600 14.3%   
Net fx Rs m-51710,980 -4.7%   
CASH FLOW
From Operations Rs m5148,942 5.8%  
From Investments Rs m-123-47,070 0.3%  
From Financial Activity Rs m-38734,174 -1.1%  
Net Cashflow Rs m4-3,655 -0.1%  

Share Holding

Indian Promoters % 32.9 71.5 45.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 7.0 2.6%  
FIIs % 0.6 12.6 4.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 8.8 754.5%  
Shareholders   20,121 26,511 75.9%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   FULFORD INDIA  AUROBINDO PHARMA  IPCA LABS  WOCKHARDT  SUVEN LIFESCIENCES  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

What Should You Do in Today's Volatile Markets?(Podcast)

The week gone by was pretty volatile for Dalal street and the global environment is as unpredictable as it can get.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Small Cap Stocks Could Triple in Less than 2 Years... Here's Why(Profit Hunter)

Sep 30, 2019

Historical data backs up my conviction.

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Sep 30, 2019

Select dividend stocks can be very rewarding.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Oct 11, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS